Synovial Sarcoma Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | EpiZyme, Merck & Co, Immunocore, Johnson & Johnson, Karyopharma
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Synovial Sarcoma pipeline constitutes 15+ key companies continuously working towards developing 20+ Synovial Sarcoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.The Synovial Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Synovial Sarcoma Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Synovial Sarcoma Market.
Some of the key takeaways from the Synovial Sarcoma Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Synovial Sarcoma treatment therapies with a considerable amount of success over the years.
*
Synovial Sarcoma companies working in the treatment market are OncoTherapy Science, Foghorn Therapeutics, BioAtla, Inc., Takara Bio, C4 Therapeutics, Adaptimmune, Epizyme, Inc., and others, are developing therapies for the Synovial Sarcoma treatment
*
Emerging Synovial Sarcoma therapies in the different phases of clinical trials are- OTSA101, FHD-609, CAB-AXL-ADC, NY-ESO-1, CFT - 8634, Afamitresgene autoleucel, Tazemetostat, and others are expected to have a significant impact on the Synovial Sarcoma market in the coming years.
*
In May 2023, To find out more about the safety and effectiveness of afamitresgene autoleucel in individuals with advanced cancer who are MAGE-A4 positive and HLA-A*02 eligible, ages 2 to 21, Adaptimmune will launch a Phase I/II pediatric basket investigation.
*
In December 2022, A rolling biologics license application (BLA) filing for the treatment of patients with advanced synovial sarcoma has been started by Adaptimmune; the submission is anticipated to be finished by mid-2023.The regenerative medicine advanced therapy (RMAT) program of the FDA will allow the application to be reviewed with priority.
Synovial Sarcoma Overview
Synovial sarcoma is a rare type of soft tissue cancer that typically arises near the joints in the arms or legs but can also develop in other soft tissues. Despite its name, synovial sarcoma does not originate from the synovium, the lining of the joints, but rather from primitive cells that resemble developing tissues.
Get a Free Sample PDF Report to know more about Synovial Sarcoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight [https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Synovial Sarcoma Drugs Under Different Phases of Clinical Development Include:
*
OTSA101: OncoTherapy Science
*
FHD-609: Foghorn Therapeutics
*
CAB-AXL-ADC: BioAtla, Inc.
*
NY-ESO-1: Takara Bio
*
CFT - 8634: C4 Therapeutics
*
Afamitresgene autoleucel: Adaptimmune
*
Tazemetostat: Epizyme, Inc.
Synovial Sarcoma Route of Administration
Synovial Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Synovial Sarcoma Molecule Type
Synovial Sarcoma Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Synovial Sarcoma Pipeline Therapeutics Assessment
*
Synovial Sarcoma Assessment by Product Type
*
Synovial Sarcoma By Stage and Product Type
*
Synovial Sarcoma Assessment by Route of Administration
*
Synovial Sarcoma By Stage and Route of Administration
*
Synovial Sarcoma Assessment by Molecule Type
*
Synovial Sarcoma by Stage and Molecule Type
DelveInsight's Synovial Sarcoma Report covers around 20+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Synovial Sarcoma product details are provided in the report. Download the Synovial Sarcoma pipeline report to learn more about the emerging Synovial Sarcoma therapies [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Synovial Sarcoma Therapeutics Market include:
Key companies developing therapies for Synovial Sarcoma are - EpiZyme Inc, Merck & Co., Inc, Immunocore Ltd, Johnson & Johnson Private Limited, Karyopharm Therapeutics Inc, Novartis AG, Pfizer Inc, F. Hoffmann-La Roche Ltd, Bayer AG, Epizyme, Cue Biopharma, Eli Lilly and Company, Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC, Takara Bio Inc, and others.
Synovial Sarcoma Pipeline Analysis:
The Synovial Sarcoma pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Synovial Sarcoma with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Synovial Sarcoma Treatment.
*
Synovial Sarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Synovial Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Synovial Sarcoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Synovial Sarcoma drugs and therapies [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Synovial Sarcoma Pipeline Market Drivers
*
Increasing Incidence of Synovial Sarcoma, increasing research and development activities for the development of targeted therapies are some of the important factors that are fueling the Synovial Sarcoma Market.
Synovial Sarcoma Pipeline Market Barriers
*
However, lack of approved therapies, adverse effects associated with the drugs and other factors are creating obstacles in the Synovial Sarcoma Market growth.
Scope of Synovial Sarcoma Pipeline Drug Insight
*
Coverage: Global
*
Key Synovial Sarcoma Companies: OncoTherapy Science, Foghorn Therapeutics, BioAtla, Inc., Takara Bio, C4 Therapeutics, Adaptimmune, Epizyme, Inc., and others
*
Key Synovial Sarcoma Therapies: OTSA101, FHD-609, CAB-AXL-ADC, NY-ESO-1, CFT - 8634, Afamitresgene autoleucel, Tazemetostat, and others
*
Synovial Sarcoma Therapeutic Assessment: Synovial Sarcoma current marketed and Synovial Sarcoma emerging therapies
*
Synovial Sarcoma Market Dynamics: Synovial Sarcoma market drivers and Synovial Sarcoma market barriers
Request for Sample PDF Report for Synovial Sarcoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Synovial Sarcoma Report Introduction
2. Synovial Sarcoma Executive Summary
3. Synovial Sarcoma Overview
4. Synovial Sarcoma- Analytical Perspective In-depth Commercial Assessment
5. Synovial Sarcoma Pipeline Therapeutics
6. Synovial Sarcoma Late Stage Products (Phase II/III)
7. Synovial Sarcoma Mid Stage Products (Phase II)
8. Synovial Sarcoma Early Stage Products (Phase I)
9. Synovial Sarcoma Preclinical Stage Products
10. Synovial Sarcoma Therapeutics Assessment
11. Synovial Sarcoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Synovial Sarcoma Key Companies
14. Synovial Sarcoma Key Products
15. Synovial Sarcoma Unmet Needs
16 . Synovial Sarcoma Market Drivers and Barriers
17. Synovial Sarcoma Future Perspectives and Conclusion
18. Synovial Sarcoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=synovial-sarcoma-pipeline-and-clinical-trials-assessment-2024-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-epizyme-merck-co-immunocore-johnson-johnson-karyopharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Synovial Sarcoma Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | EpiZyme, Merck & Co, Immunocore, Johnson & Johnson, Karyopharma here
News-ID: 3489427 • Views: …
More Releases from ABNewswire
Military Laser Systems Market Set for Impressive Growth by USD 7.5 Billion by 20 …
The Military Laser Systems Market Size, Share, Industry Growth, Trends & Analysis is reach to USD 7.5 Billion by 2028 from USD 5.0 Billion in 2023, at a CAGR of 8.7%.
The global Military Laser Systems [https://www.marketsandmarkets.com/Market-Reports/military-laser-systems-market-154285551.html] Market is poised for significant expansion over the forecast period, "The Global Military Laser Systems Market by Application, Technology, Platform, End Use, Output Power, and Region - Global Forecast to 2028." The report offers…
KingKonree Unveils Cutting-Edge Innovations at the Canton Fair
Leading solid surface manufacturer showcases new product ranges and sustainable design solutions.
KingKonree International [http://www.kingkonree.com/], a prominent manufacturer specializing in solid surface sanitary ware, countertops, and sheets, has significantly impacted the 135th Canton Fair. The "KKR Sanitary Ware Exhibition" highlighted KingKonree's innovative capabilities and emphasized its commitment to sustainable practices and global trade cooperation.
According to the company, KingKonree's exhibition hall at the Canton Fair was a hub of activity, drawing attention…
Cross Linking Agents MarketSize, Growth, Opportunities, Top Manufacturers, Share …
The Cross Linking Agents Market experiences robust demand globally, driven by diverse industries such as automotive, construction, and electronics. Asia-Pacific leads with rapid urbanization, infrastructure growth, and increasing disposable incomes fostering significant market growth.
The Cross Linking Agent market [https://www.marketsandmarkets.com/Market-Reports/crosslinking-agent-market-266941939.html] size is projected to grow from USD 9.9 billion in 2023 to USD 13.6 billion by 2028, registering a CAGR of 6.5% during the forecast period. The growing demand for high-performance…
Love Pines Realty Announces Southern Pines Cottage Home for Sale
Located at 875 N May St, Southern Pines
May 29, 2024 - Are you absolutely smitten with downtown Southern Pines? Here is your chance to purchase a cute cottage! Opportunity to build out your living space!
Image: https://www.abnewswire.com/uploads/5b1ba49c1630221023d7eff27f9a01e7.png
The lifestyle of small-town living is romantically captured here. Downtown Southern Pines is friendly, hip, and charming. Don't miss out on this lock and leave Cottage for Sale.
Welcome to Southern Pines. This home is centrally…
More Releases for Synovial
Synovial Sarcoma Treatment Market Revenue Opportunies By Key Vendors Synovial Sa …
Synovial sarcoma consists of abnormal growth of soft-tissue. Synovial sarcoma is a rare type of cancer and is more prevalent in teenagers and young adults. Synovial sarcoma is highly metastatic and spreads to other places, in almost 50% of the cases and lungs are the common site for metastasis to occur. The cause behind occurrence of synovial sarcoma have not yet been established, however, it is found to be associated…
Synovial Sarcoma Treatment Market - Global Industry Insights, Trends, 2026
Synovial sarcoma consists of abnormal growth of soft-tissue. Synovial sarcoma is a rare type of cancer and is more prevalent in teenagers and young adults. Synovial sarcoma is highly metastatic and spreads to other places, in almost 50% of the cases and lungs are the common site for metastasis to occur. The cause behind occurrence of synovial sarcoma have not yet been established, however, it is found to be associated…
Synovial Sarcoma - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Synovial Sarcoma - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H2 2017, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.
Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or…
Synovial Sarcoma Market Forecast Research Reports Offers Key Insights
Synovial sarcoma is a predominantly juxta-articular, malignant, and soft-tissue tumour, which represents approximately 10% of all soft-tissue sarcomas. It was first reported in 1893, and due to its resembling characteristic with synovium, it was named as synovial sarcoma. As per the studies it has been observed that, synovial sarcomas are slow growing tumours and usually occur predominantly around knees, followed by the ankle, shoulder and elbow. Rise in incidence rate…
Synovial Sarcoma Pipeline Insight and Therapeutic Assessment Reviewed in 2017
Market Research Hub's latest Pharmaceutical and “Healthcare disease pipeline guide Synovial Sarcoma Pipeline Review”, H2 2017, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.
Request For Free Sample - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305536
Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty…
Synovial Sarcoma Pipeline Insight and Therapeutic Assessment 2017
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Synovial Sarcoma-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Synovial Sarcoma. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Synovial Sarcoma by development stage, therapy type, route of administration…